MeiraGTx Holdings plc (NASDAQ:MGTX - Get Free Report) CFO Richard Giroux sold 24,000 shares of MeiraGTx stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $6.00, for a total transaction of $144,000.00. Following the sale, the chief financial officer now owns 882,494 shares in the company, valued at $5,294,964. This represents a 2.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
MeiraGTx Stock Up 11.0 %
Shares of NASDAQ:MGTX opened at $6.27 on Wednesday. MeiraGTx Holdings plc has a 12-month low of $3.85 and a 12-month high of $8.75. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.86. The firm has a market cap of $494.42 million, a PE ratio of -5.18, a price-to-earnings-growth ratio of 0.37 and a beta of 1.21. The company has a fifty day simple moving average of $6.55 and a 200 day simple moving average of $6.25.
MeiraGTx (NASDAQ:MGTX - Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.02). The company had revenue of $21.39 million during the quarter, compared to analyst estimates of $1.50 million. MeiraGTx had a negative net margin of 633.05% and a negative return on equity of 146.38%. On average, equities research analysts anticipate that MeiraGTx Holdings plc will post -1.48 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
MGTX has been the topic of several analyst reports. Royal Bank of Canada lifted their price target on shares of MeiraGTx from $11.00 to $13.00 and gave the stock an "outperform" rating in a research note on Monday, March 17th. Chardan Capital reiterated a "buy" rating and issued a $36.00 price target on shares of MeiraGTx in a research note on Monday, February 24th.
Read Our Latest Research Report on MGTX
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the company. Sanofi acquired a new position in MeiraGTx in the fourth quarter worth $74,284,000. Woodline Partners LP bought a new stake in shares of MeiraGTx during the 4th quarter valued at about $9,349,000. State Street Corp raised its stake in MeiraGTx by 0.9% during the third quarter. State Street Corp now owns 574,727 shares of the company's stock worth $2,397,000 after acquiring an additional 5,251 shares during the period. Geode Capital Management LLC lifted its holdings in MeiraGTx by 16.4% in the fourth quarter. Geode Capital Management LLC now owns 570,646 shares of the company's stock worth $3,475,000 after acquiring an additional 80,407 shares during the last quarter. Finally, Garden State Investment Advisory Services LLC acquired a new position in MeiraGTx in the third quarter valued at approximately $1,636,000. Institutional investors and hedge funds own 67.48% of the company's stock.
About MeiraGTx
(
Get Free Report)
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
